Profil
Martin Bott served as the VP-Corporate Finance & Investment Banking at Eli Lilly & Co. from 2015 to 2017.
He also served as an Independent Director at InMed Pharmaceuticals, Inc. from 2017 to 2019 and as a Director at CoLucid Pharmaceuticals, Inc. Additionally, he received an undergraduate degree from Universität zu Köln in 1985 and a graduate degree from the University of South Carolina in 1988.
Ehemalige bekannte Positionen von Martin Bott
| Unternehmen | Position | Ende |
|---|---|---|
| INMED PHARMACEUTICALS INC. | Direktor/Vorstandsmitglied | 31.08.2019 |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01.12.2017 |
| COLUCID PHARMACEUTICALS INC | Direktor/Vorstandsmitglied | - |
Ausbildung von Martin Bott
| University of South Carolina | Graduate Degree |
| Universität zu Köln | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INMED PHARMACEUTICALS INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Private Unternehmen | 1 |
|---|---|
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. BiotechnologyHealth Technology CoLucid Pharmaceuticals, Inc. engaged in the development of therapeutics for neurological disorders. Its products included Lasmiditan, a neurally acting anti-migraine agent that is designed to delivered efficacy in migraine without the vasoconstrictor activity associated with previous generations of migraine therapies and a Conjugated Stigmines platform that has generated a series of preclinical candidates for the chronic pain, Alzheimer's disease and psychiatric disorders. The company was founded by James F. White and Arthur M. Pappas in 2005 and was headquartered in Cambridge, MA. | Health Technology |
